ClinicalTrials.gg
Active, not recruitingNCT06848348Updated Sep 16, 2026

Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

A Phase 2 interventional study of Halneuron and Placebo in Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy and Chemotherapy Induced Pain, sponsored by Dogwood Therapeutics Inc.. Active, not recruiting at 25 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.

Primary conditionNeuralgiaRegistry: PainReclassifiedWhy we changed it
Registry
Pain — the first condition term the registry derived for this study.
ClinicalTrials.gg
Neuralgia
Why
  1. The study's listed conditions name Neuralgia, a narrower term within Pain.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Dogwood Therapeutics Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 291 studies in Neuralgia with a site in United States — 50 open to participants now, 61 under way, 5 of them phase 3. Neuralgia · United States.

Planned enrollment
29th of 261
240 · median 40
Started
2025
with 12 others
Phase 2
78 of 291
5 open now
Primary completion
2026-12
later than 13 of 60 live
Registered
267th of 291
by date

Among the 291 studies in Neuralgia with a site in United States, this one is the 29th largest by planned enrollment of the 261 interventional ones that give a count, is one of 13 that started in 2025, is one of 78 in phase 2, reaches primary completion later than 13 of the 60 other live ones, and was the 267th registered.

Neuralgia

1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.

Browse Neuralgia studies →

Open to participants now

50 of the 291 studies in Neuralgia with a site in United States are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 291 studies in Neuralgia with a site in United States, or all of them as a file.
02

Study summary

A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections. After that, subjects may have the option to enter an Open Label extension phase, where available, in which all subjects will receive Halneuron.

03

Conditions studied

  • Chemotherapy Induced Neuropathic Pain
  • Chemotherapy Induced Pain Neuropathy
  • Chemotherapy Induced Pain

Keywords

  • Chemotherapy
  • Pain
  • Neuropathy
  • Cancer
  • CIPN
  • CINP
  • Chemotherapy Induced
  • Neuropathic Pain
  • Breast Cancer
  • Colorectal Cancer
  • Cancer Pain
  • Peripheral Neuropathy
04

In context

Neuralgia Reclassified

1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.

This study's planned enrollment of 240 is above the median of 52 across 832 interventional studies indexed under Neuralgia.

Browse Neuralgia studies →

Lead sponsor

This is the only study on the registry with Dogwood Therapeutics Inc. as lead sponsor.

Compared within Neuralgia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients aged ≥18 years.
  • Neuropathic pain has been present and is attributed to platinum and/or taxane chemotherapy.
  • Patient has received a cancer chemotherapy regimen that included taxanes and/or platinum and has no active or discernible disease progression.

Exclusion criteria

Exclusion Criteria:

  • Current neuropathic pain with symptoms similar to CINP but attributed to causes other than platinum or taxane chemotherapy.
  • Patients who have received HAL at any time prior to screening.
06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

  • Experimental
    Halneuron

    Halneuron

    Drug: Halneuron

  • Active comparator
    Open Label Extension

    Subjects may choose to continue in an Open Label Extension (OLE) phase if they complete the randomized phase. All subjects regardless of treatment assignment in the randomized phase will receive Halneuron, during the OLE phase of the study, if offered by the clinical site.

    Drug: Halneuron · Drug: Halneuron (Open Label Extension)

Interventions

  • Halneuron for Subcutaneous Injection

  • DrugPlacebo

    Placebo for Subcutaneous Injection

  • DrugHalneuron (Open Label Extension)

    Halneuron for Subcutaneous Injection

07

What researchers measure

Primary outcomes

  1. NRS Pain

    Change from Baseline in the weekly average of daily 24-hour pain intensity scores analyzed by percentage of responders among patients treated with Halneuron compared to Placebo

    Time frame: From enrollment to end of study at 4 weeks

  2. Safety Assessments

    Incidence of serious adverse events (SAEs), adverse events (AEs) and Adverse Events of Special Interests (AESIs)

    Time frame: From enrollment to end of study at 4 weeks

Secondary outcomes

  1. Patient Global Impression of Change (PGIC)

    Patient Global Impression of Change (PGIC)

    Time frame: Enrollment to end of study at week 4

  2. PROMIS Fatigue

    Change from baseline to week 4 on the PROMIS Fatigue instrument

    Time frame: Enrollment to end of study at week 4

  3. PROMIS Sleep

    Change from baseline to week 4 on PROMIS Sleep instrument

    Time frame: Enrollment to end of study at week 4

  4. PROMIS-29 Quality of Life

    Change from baseline to week 4 on the domains of the PROMIS-29 instrument

    Time frame: Enrollment to end of study at week 4

08

Study locations

25 sites
  • Central Recruiting Site
    Sheffield, Alabama 35660, United States
  • Central Recruiting Site
    Glendale, Arizona 85308, United States
  • Central Recruiting Site
    Phoenix, Arizona 85022, United States
  • Central Recruiting Site
    Fair Oaks, California 95628, United States
  • Central Recruiting Site
    Fountain Valley, California 92708, United States
  • Central Recruiting Site
    Los Angeles, California 91307, United States
  • Central Recruiting Site
    Santa Rosa, California 95403, United States
  • Central Recruiting Site
    Wheat Ridge, Colorado 80033, United States
  • Central Recruiting Site
    Jacksonville, Florida 32205, United States
  • Central Recruiting Site
    Jacksonville, Florida 32256, United States
  • Central Recruiting Site
    Lakeland, Florida 33812, United States
  • Central Recruiting Site
    Orlando, Florida 32832, United States
  • Central Recruiting Site
    Port Charlotte, Florida 33952, United States
  • Central Recruiting Site
    Tampa, Florida 33613, United States
  • Central Recruiting Site
    Gurnee, Illinois 60031, United States
  • Central Recruiting Site
    Lake Charles, Louisiana 70605, United States
  • Central Recruiting Site
    Fenton, Missouri 63026, United States
  • Central Recruiting Site
    Las Vegas, Nevada 89109, United States
  • Central Recruiting Site
    Garden City, New York 11530, United States
  • Central Recruiting Site
    Williamsville, New York 14221, United States
  • Central Recruiting Site
    Winston-Salem, North Carolina 27103, United States
  • Central Recruiting Site
    Houston, Texas 77346, United States
  • Central Recruiting Site
    McAllen, Texas 78504, United States
  • Central Recruiting Site
    Salt Lake City, Utah 84107, United States
  • Central Recruiting Site
    Madison, Wisconsin 53715, United States
09

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Clinical study report

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.

Of 34 industry-sponsored phase 2 interventional studies under Neuralgia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 22. This study's planned 22 months is above that.

Counting every sponsor, half of 58 studies reached it within 22 months; a quarter within 11 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2025
First posted
Feb 27, 2025
StartActual
Feb 21, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06848348
Lead sponsor
Dogwood Therapeutics Inc.
Responsible party
Sponsor
First posted
Feb 27, 2025
Start date
Feb 21, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tetrodotoxin

Start the discussion